HDT Bio Corp
Seattle, WA
- UEI
- Z33DCMWXZBK7
- CAGE
- 7YDE0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1150 Eastlake Ave E #200a, Seattle, WA 98109, USA
- Website
- hdt.bio
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Research service | Bureau of Medicine and Surgery | $129,000 | |
| Immunological mechanism of muscle-localizing self-replicating RNA vaccines - project summary/abstract as evident in… | National Institute of Allergy and Infectious Diseases | $6,032,395 | |
| PA21259, sbir phase i, developing a RIG-i agonist to prevent covid-19 | Office of Financial Resources | $599,901 | |
| HDT BIO corp - AOI #21 vaccine on demand: r & d use of lion-reprna in rapid response vaccine development | Office of the Assistant Secretary for Preparedness and Response | $749,000 | |
| Development of a RIG-i agonist RNA as a cure for chronic hepatitis b - project summary: despite the availability of a… | National Institute of Allergy and Infectious Diseases | $275,211 |
About HDT Bio Corp
HDT Bio Corp is a Seattle-based biopharmaceutical company specializing in developing innovative RNA-based vaccines, therapeutics, and drug delivery platforms. The company focuses on creating advanced medical solutions for infectious diseases, cancer, and other unmet medical needs, primarily working with self-replicating RNA (RepRNA) technologies and lipid inorganic nanoparticle (LION) delivery systems. Through its federal contract and grant awards, HDT Bio Corp provides research and development services to multiple federal agencies, with a particular emphasis on vaccine development, antiviral strategies, and advanced immunological technologies.
HDT Bio Corp has received federal contract awards primarily from agencies like the National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), and the Office of the Assistant Secretary for Preparedness and Response (ASPR). These contracts have focused on developing rapid response vaccine technologies, such as a $749,000 contract for "Vaccine on Demand" research utilizing their Lion-ReRNA technology and a $1.5 million contract to develop an adaptable RNA-based antibody platform for protecting against contemporary and emerging human enteroviruses. The company has also received a significant $11 million contract to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein, through Phase I clinical trials. None of these contracts involved specific set-aside designations, and the work has been performed as definitive contracts with clear research and development objectives.
HDT Bio Corp's federal grant awards demonstrate a broad range of research initiatives across infectious diseases, vaccine development, and innovative medical technologies. The company has received grants from agencies including NIAID, the National Cancer Institute, and the Defense Health Agency. Notable grant projects include developing a muscle-localizing self-replicating RNA vaccine platform, creating a RIG-I agonist to prevent COVID-19, developing treatments for chronic hepatitis B, and engineering RNA vaccines for HIV-1. The company has also participated in sub-grant awards with prestigious institutions like Albert Einstein College of Medicine, University of Washington, and Tufts College, working on projects such as prepositioning vaccine strategies against emerging infectious threats, developing vaccines to prevent colorectal cancer, and exploring immune-based therapies. These grants typically range from small business innovation research (SBIR) Phase I awards to more comprehensive multi-year research projects, highlighting HDT Bio Corp's versatility and innovative approach to medical research.
Quick answers
What is HDT Bio Corp's UEI?
HDT Bio Corp's Unique Entity ID (UEI) in SAM.gov is Z33DCMWXZBK7.
What is HDT Bio Corp's CAGE code?
HDT Bio Corp's CAGE code is 7YDE0.
What is HDT Bio Corp's primary NAICS code?
HDT Bio Corp's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is HDT Bio Corp located?
HDT Bio Corp's physical address in SAM.gov is 1150 Eastlake Ave E #200a, Seattle, WA 98109, USA.
Is HDT Bio Corp registered in SAM.gov?
Yes. HDT Bio Corp's SAM.gov registration is active through September 28, 2027.
What is HDT Bio Corp's most recent federal award?
HDT Bio Corp's most recent federal contract award is Research service (N3239825PA019), from Bureau of Medicine and Surgery, on April 14, 2025.
On GovTribe
See HDT Bio Corp's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors